The FDA has updated its compounding guidelines for licensed pharmacies, hospitals, and health systems.
The FDA has issued immediately in-effect guidance to increase supplies of pediatric ibuprofen, which, as a result of infections stemming from COVID-19, influenza, and RSV, has been in high demand this winter.
The report notes, "the United States is currently experiencing a significant number of infections involving 3 viruses: COVID-19, RSV, and influenza. Each of these viruses may produce fever in young children ... the FDA is issuing this policy to provide temporary flexibility to help ensure that treatment options are available when hospitals, health systems, state-licensed pharmacies, and applicable federal facilities are unable to obtain ibuprofen oral suspension drug products to use for fever and pain treatment of pediatric patients and adults who are unable to swallow solid oral dosage form products."
The FDA continues to monitor the global pharmaceutical supply chain and is working with manufacturers to bolster supply, but notes that some temporary flexibility is needed to insure ibuprofen is available during this period of increased demand. The guidance includes steps that outsourcing facilities should take to reduce the risks associated with compounded products, including, but not limited to:
-ibuprofen oral suspension products have a concentration of 100 mg/5mL
-each shipment be tested for identity and evaluted for conformity with appropriate specifications before use in compounding
-the outsourcing facility perform a limit test for diethylene glycol (DEG) and ethylene glycol (EG) on all containers of all lots at a higher risk of DEG and EG contamination.
-the ibuprofen oral suspension formulation is compounded using sterile water that complies with USP sterile water monograph
You can read the full report here.
This article originally appeared on Contemporary Pediatrics.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.